Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial

Publish Year: 1397
نوع سند: مقاله ژورنالی
زبان: English
View: 329

This Paper With 11 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_AJP-8-6_006

تاریخ نمایه سازی: 18 تیر 1398

Abstract:

Objective: Saffron was found efficient and safe in treatment of neuropsychiatric disorders, in particular depression. We compared the efficacy of saffron with duloxetine in treatment of patients with fibromyalgia. Materials and Methods: In this double-blind parallel-group clinical trial, outpatients with fibromyalgia were randomized to receive either saffron 15 mg or duloxetine 30 mg starting with 1 capsule per day in the first week followed by 2 capsules per day from week 2 until the end of week 8. Participants were men and women aged 18-60 years diagnosed with fibromyalgia based on the American College of Rheumatology 2010 criteria who also had a pain score ≥40 based on visual analogue scale. Participants were excluded in case they had rheumatologic diseases, inflammatory/infectious/autoimmune arthritis, comorbid neuropsychiatric disorders except depressive disorders, pain due to traumatic injuries, drug history of duloxetine or saffron use, current use of psychoactive medications, recent use of muscle relaxants, steroids, opioid analgesics, benzodiazepines, anti-epileptics, or injective analgesics. Primary outcomes included differences in mean score changes from baseline to endpoint between the treatment arms for Hamilton Rating Scale for Depression, Fibromyalgia Impact Questionnaire, and Brief Pain Inventory. Results: Socio-demographic characteristics and baseline scores were similarly distributed between the two treatment arms (2n=46). No significant difference was detected for any of the scales neither in terms of score changes from baseline to endpoint between the two treatment arms (Mean score changes: -4.26 to 2.37; p-values: 0.182-0.900) nor in terms of time´treatment interactions (p-values: 0.209-0.964). Conclusions: Saffron and duloxetine demonstrated comparable efficacy in treatment of fibromyalgia symptoms.

Authors

Mansoor Shakiba

Psychosomatic Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran

Ehsan Moazenzadeh

Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

Ahmad Ali Noorbala

Psychosomatic Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran

Morteza Jafarinia

Psychosomatic Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Ablin JN, Häuser W. 2016. Fibromyalgia syndrome: novel therapeutic targets. ...
  • Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi A-H, Khalighi-Cigaroudi F. ...
  • American Psychiatric Association. 2000. DSM-IV-TR: Diagnostic and statistical manual of ...
  • Amin B, Hosseini S, Hosseinzadeh H. 2017. Enhancement of Antinociceptive ...
  • Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, ...
  • Basti AA, Moshiri E, Noorbala A-A, Jamshidi A-H, Abbasi SH, ...
  • Becker S, Schweinhardt P. 2012. Dysfunctional neurotransmitter systems in fibromyalgia, ...
  • Burckhardt CS, Clark SR, Bennett RM. 1991. The fibromyalgia impact ...
  • Calandre EP, Rico-Villademoros F, Slim M. 2015. An update on ...
  • Carlsson AM. 1983. Assessment of chronic pain. I. Aspects of ...
  • Chinn S, Caldwell W, Gritsenko K. 2016. Fibromyalgia pathogenesis and ...
  • Cleeland CS, Ryan KM. 1994. The Brief Pain Inventory. Ann ...
  • Cordero MD, de Miguel M, Carmona-López I, Bonal P, Campa ...
  • De Souza Nascimento S, DeSantana JM, Nampo FK, Ribeiro ÊA, ...
  • Ghajar A, Neishabouri SM, Velayati N, Jahangard L, Matinnia N, ...
  • Ghavidel-Parsa B, Amir Maafi A, Haghdoost A, Arabi Y, Khojamli ...
  • Ghavidel-Parsa B, Bidari A, Amir Maafi A, Ghalebaghi B. 2015. ...
  • Gracely RH, Ceko M, Bushnell MC. 2012. Fibromyalgia and depression. ...
  • Hamilton M. 1960. A rating scale for depression. J Neurol ...
  • Hausenblas HA, Saha D, Dubyak PJ, Anton SD. 2013. Saffron ...
  • Häuser W, Petzke F, Sommer C. 2010. Comparative efficacy and ...
  • Häuser W, Urrútia G, Tort S, Üçeyler N, Walitt B. ...
  • Häuser W, Henningsen P. 2014a. Fibromyalgia syndrome: a somatoform disorder ...
  • Häuser W, Walitt B, Fitzcharles M-A, Sommer C. 2014b. Review ...
  • Hewlett S, Dures E, Almeida C. 2011. Measures of fatigue: ...
  • Kashani L, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, ...
  • Kashani L, Eslatmanesh S, Saedi N, Niroomand N, Ebrahimi M, ...
  • Kashani L, Eslatmanesh S, Eftekhari F, Salimi S, Foroughifar T, ...
  • Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, Tsatsakis AM. ...
  • Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, ...
  • Lauche R, Cramer H, Häuser W, Dobos G, Langhorst J. ...
  • Lawson K. 2016. Potential drug therapies for the treatment of ...
  • Lopresti AL, Drummond PD. 2014. Saffron (Crocus sativus) for depression: ...
  • Luciano JV, Forero CG, Cerdà-Lafont M, Peñarrubia-María MT, Fernández-Vergel R, ...
  • Maletic V, Raison CL. 2009. Neurobiology of depression, fibromyalgia and ...
  • Mazidi M, Shemshian M, Mousavi SH, Norouzy A, Kermani T, ...
  • Meeus M, Nijs J, Hermans L, Goubert D, Calders P. ...
  • Milajerdi A, Bitarafan V, Mahmoudi M. 2015. A review on ...
  • Moazen-Zadeh E, Abbasi SH, Safi-Aghdam H, Shahmansouri N, Arjmandi-Beglar A, ...
  • Modabbernia A, Sohrabi H, Nasehi AA, Raisi F, Saroukhani S, ...
  • Moshiri M, Vahabzadeh M, Hosseinzadeh H. 2015. Clinical applications of ...
  • Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. 2005. Hydro-alcoholic ...
  • Pae CU, Luyten P, Marks DM, Han C, Park SH, ...
  • Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, ...
  • Queiroz LP. 2013. Worldwide epidemiology of fibromyalgia. Curr Pain Headache ...
  • Sadreddini S, Molaeefard M, Noshad H, Ardalan M, Asadi A. ...
  • Safakhah HA, Taghavi T, Rashidy-Pour A, Vafaei AA, Sokhanvar M, ...
  • Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. ...
  • Schmidt-Wilcke T, Clauw DJ. 2011. Fibromyalgia: from pathophysiology to therapy. ...
  • Schumi J, Wittes JT. 2011. Through the looking glass: understanding ...
  • Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Tafti AA, ...
  • Sluka KA, Clauw DJ. 2016. Neurobiology of fibromyalgia and chronic ...
  • Theoharides TC, Tsilioni I, Arbetman L, Panagiotidou S, Stewart JM, ...
  • Thiagarajah AS, Guymer EK, Leech M, Littlejohn GO. 2014. The ...
  • Üçeyler N, Sommer C, Walitt B, Häuser W. 2013. Anticonvulsants ...
  • Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, ...
  • Zigmond AS, Snaith RP. 1983. The hospital anxiety and depression ...
  • نمایش کامل مراجع